미국 - 영어 - NLM (National Library of Medicine)

bausch health us, llc - secobarbital sodium (unii: xbp604f6um) (secobarbital - unii:1p7h87in75) - secobarbital sodium 100 mg - seconal sodium is contraindicated in patients who are hypersensitive to barbiturates. it is also contraindicated in patients with a history of manifest or latent porphyria, marked impairment of liver function, or respiratory disease in which dyspnea or obstruction is evident. abuse and addiction are separate and distinct from physical dependence and tolerance. abuse is characterized by misuse of the drug for non-medical purposes, often in combination with other psychoactive substances. physical dependence is a state of adaptation that is manifested by a specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug and/or administration of an antagonist. tolerance is a state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the drug's effects over time. tolerance may occur to both the desired and undesired effects of drugs and may develop at different rates for different effects. addiction is

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

martindale pharmaceuticals ltd - phenobarbital sodium - solution for injection - 200mg/1ml

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

martindale pharmaceuticals ltd - phenobarbital sodium - solution for injection - 60mg/1ml

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

martindale pharmaceuticals ltd - phenobarbital sodium - solution for injection - 30mg/1ml

캐나다 - 영어 - Health Canada

hospira healthcare ulc - phenobarbital sodium - solution - 120mg - phenobarbital sodium 120mg - barbiturates

캐나다 - 영어 - Health Canada

hospira healthcare ulc - phenobarbital sodium - solution - 30mg - phenobarbital sodium 30mg - barbiturates

케냐 - 영어 - Pharmacy and Poisons Board

tasa pharma ltd kay complex, unit c1-c3 kay complex, mombasa rd, - phenobarbital sodium - solution for injection - 200mg/ml - phenobarbital

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - sodium valproate, quantity: 1000 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - sodium valproate, quantity: 400 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

미국 - 영어 - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - phenobarbital sodium (unii: sw9m9bb5k3) (phenobarbital - unii:yqe403bp4d) - sezaby is indicated for the treatment of neonatal seizures in term and preterm infants. sezaby is contraindicated in patients with: - acute porphyrias [see warnings and precautions (5.8)], or - a history of hypersensitivity reaction to phenobarbital or other barbiturates [see warnings and precautions (5.7)] the safety and effectiveness of sezaby have been established for the treatment of neonatal seizures in term and preterm infants, and the information on this use is discussed throughout the labeling. juvenile animal studies in published studies, administration of antiepileptic drugs, including phenobarbital, to neonatal rats during the period of synaptogenesis has been reported to result in widespread apoptotic neurodegeneration in the developing brain and neurobehavioral deficits that persist into adulthood at doses associated with plasma exposures similar to those anticipated at the doses proposed for humans. the synaptogenetic period in rats is generally thought to correspond in humans to the third trim